Physician profile
David Gwynn
NPI 1003837766
$13,733.37
in general payments reported to CMS, 2019-2025
20 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,713 · 2020: $1,862 · 2021: $2,285 · 2022: $1,914 · 2023: $1,416 · 2024: $1,230 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Entertainment: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.57 |
| Entertainment | $212.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,991.30 | 2019-2025 | Clareon, Argos, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $1,067.12 | 2019 | |
| Bausch & Lomb Americas INC. | $930.58 | 2024-2025 | Envista Envy Iol, Miebo, Xiidra |
| Allergan, INC. | $498.05 | 2019-2021 | |
| Amgen INC. | $313.31 | 2024-2025 | Tepezza |
| Optos, INC. | $263.61 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $256.43 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $241.15 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $227.52 | 2019-2025 | Cequa |
| Shire North American Group INC | $199.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $181.26 | 2019-2022 | |
| Horizon Therapeutics Plc | $132.01 | 2022-2023 | Tepezza |
| Biotissue Holdings INC. | $115.37 | 2020-2024 | |
| Alcon Research LLC | $91.71 | 2019 | |
| Oyster Point Pharma, INC. | $80.62 | 2022-2025 | Tyrvaya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $58.12 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.47 | 2021 | |
| Eyevance Pharmaceuticals LLC | $22.27 | 2019 | |
| Thea Pharma INC. | $20.21 | 2024 | Iyuzeh |
| Beaver-Visitec International, INC. | $18.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gwynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.